Celcuity, Inc. (NASDAQ:CELC) Stock Has Average Target Price of $152.57

Celcuity, Inc. (NASDAQ:CELC) has earned a consensus rating of “Moderate Buy” from the sixteen analysts that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating and thirteen have issued a buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $152.57.

Several research firms have recently weighed in on CELC. TD Cowen reaffirmed a “buy” rating and set a $145.00 price objective on shares of Celcuity in a research report on Wednesday, October 21st. Zacks Research lowered Celcuity from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 13th. Needham & Company LLC dropped their target price on Celcuity from $140.00 to $134.00 and set a “buy” rating on the stock in a research report on Wednesday, September 30th. Craig Hallum restated a “buy” rating and issued a $178.00 target price on shares of Celcuity in a research note on Wednesday, July 15th. Finally, Royal Bank Of Canada lowered shares of Celcuity to a “neutral” rating in a research report on Wednesday, October 28th.

Institutional Trading of Celcuity

Several institutional investors and hedge funds have recently bought and sold shares of CELC. Hsbc Holdings PLC bought a new position in Celcuity during the fourth quarter worth about $1,058,000. California State Teachers Retirement System raised its stake in Celcuity by 91.2% in the first quarter. California State Teachers Retirement System now owns 25,580 shares of the company’s stock valued at $2,920,000 after buying an additional 12,201 shares during the period. Bank of America Corp DE acquired a new stake in shares of Celcuity in the second quarter valued at approximately $153,928,000. E Fund Management Co. Ltd. acquired a new stake in shares of Celcuity in the second quarter valued at approximately $4,802,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Celcuity in the second quarter valued at approximately $2,927,000. Institutional investors own 63.33% of the company’s stock.

Celcuity Price Performance

Shares of CELC opened at $67.07 on Tuesday. The stock has a 50 day simple moving average of $77.14 and a 200 day simple moving average of $100.19. Celcuity has a 52-week low of $53.54 and a 52-week high of $151.02. The company has a current ratio of 8.93, a quick ratio of 8.93 and a debt-to-equity ratio of 6.04.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28). On average, sell-side analysts forecast that Celcuity will post -4.98 EPS for the current fiscal year.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company developing functional diagnostic tests designed to help identify cancer treatments that may be most effective for individual patients. Its technology analyzes living tumor cells taken from patients to measure how signaling pathways respond to different therapies, with the goal of supporting more personalized treatment decisions.

The company’s CELsignia platform is designed to assess the activity of cancer-related signaling pathways in patient-derived cells.